Veracyte, Inc. is a global cancer diagnostics company that develops molecular tests to guide clinical decision-making in thyroid, prostate, breast, bladder, and lung cancers. The company offers laboratory developed tests (LDTs) in the United States through its own CLIA-certified laboratories and in vitro diagnostic (IVD) tests internationally via distribution to laboratories and hospitals. Its portfolio includes the Decipher Prostate Genomic Classifier for risk assessment in prostate cancer, the Afirma Genomic Sequencing Classifier for thyroid nodules, the Prosigna Breast Cancer Prognostic Gene Signature Assay, and the Decipher Bladder Genomic Classifier. Veracyte is also developing the TrueMRD minimal residual disease platform and the Percepta Nasal Swab test for lung cancer. The company utilizes a whole-transcriptome approach combined with bioinformatics and artificial intelligence to analyze tumor biology. It serves clinicians and patients in the United States and international markets, with operations supported by facilities in California and Texas, and an office in Israel. Veracyte went public in October 2013.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage veracyte.com
Sector Healthcare IR page investor.veracyte.com
Tags
cancer diagnostics, genomic testing, prostate cancer, thyroid cancer, breast cancer, bladder cancer, lung cancer, molecular diagnostics, laboratory developed tests, in vitro diagnostics, minimal residual disease, bioinformatics, Decipher Prostate, Afirma, Prosigna, Decipher Bladder, TrueMRD, Percepta Nasal Swab, Veracyte Diagnostics Platform, GRID database
Press page —

Metrics

Valuation  
Market cap $ 4.033B
Market cap (USD) $ 4.033B
P/E 32.47
PEG —
P/BV 2.81
P/S 6.93
P/OCF 23.19
P/FCF 24.90
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.3%
ROI 6.8%
ROIC 5.7%
Profit margin 12.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 82
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 517.145M 445.764M 361.051M 296.536M 219.514M 117.483M 120.368M 92.008M 71.953M 65.085M 49.503M 38.19M 21.884M 11.628M
Net profit 66.353M 24.138M -74.404M -36.56M -75.563M -34.909M -12.599M -22.999M -31.003M -31.358M -33.704M -29.373M -25.58M -18.649M
Free cash flow 126.63M 63.809M 34.261M -1.014M -36.997M -12.548M -5.988M -15.395M -25.67M -32.192M -33.13M -29.656M -20.491M -8.629M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 42.1 39.6 27.51 23.73 41.2 48.94 27.92 12.58 6.53 7.74 7.2 9.66 14.5 —
Price performance 12m 0.06 0.44 0.16 -0.42 -0.16 0.75 1.22 0.93 -0.16 0.07 -0.25 -0.33 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 8.76M 12.7M 13.2M 19.3M 18.5M 41.5M 44M 40.4M 46.5M 44.7M
↳ YoY growth +150.0% +45.2% +3.6% +46.8% -4.5% +124.6% +6.2% -8.3% +15.2% -4.0%
↳ 5y CAGR +86.1% +63.0% +44.7% +39.4% +36.5% +28.2% +25.1% +19.2% +19.3%
Borrowings, current (USD) — 0.00 1.36M 0.00 0.00 1.13M 0.00 — — —
Borrowings, non-current (USD) 24.9M 24.9M 23.9M 694,000 810,000 0.00 — — — —
Lease liabilities (USD) — — 0.00 12.9M 11.5M 17.7M 14.7M 12.6M 50.7M 39.7M
Cash and deposits (USD) 59.2M 33.9M 78M 159M 349M 173M 154M 216M 239M 363M
Intangible assets (USD) 14.1M 13.1M 12M 65M 59.9M 203M 175M 88.6M 102M 89.1M
Right-of-use assets (USD) — — 0.00 8.81M 7.84M 16M 13.2M 10.3M 48.2M 36.6M
Net debt (borrowings + leases - cash) (USD) -34.3M -8.95M -52.7M -146M -337M -154M -140M — — —
Cash flow detail
Operating cash flow (USD) -28M -23.9M -13.5M -3.23M -9.71M -31.6M 7.54M 44.2M 75.1M 136M
Purchases of property, plant and equipment (USD) -4.21M -1.76M -1.87M -2.76M -2.84M -5.38M -8.55M -9.96M -11.3M -9.68M
Change in receivables (cash effect) (USD) -5.32M -3.96M -452,000 -6.16M 955,000 -8.57M -4.5M 3.89M -6.41M -708,000
Change in inventories (cash effect) (USD) 292,000 -1.85M 1.92M -3.4M 1.06M -1.46M -3.01M -1.69M -5.87M -2.86M
Change in payables (cash effect) (USD) -1.44M 1.73M -1.57M -141,000 711,000 5.16M 152,000 -134,000 -4.31M -1.04M
Interest paid (cash effect) (USD) -2.15M -2.72M -1.55M -332,000 -13,000 -9,000 -9,000 0.00 0.00 —
Income taxes paid (cash effect) (USD) -7,000 -21,000 -79,000 -35,000 -112,000 -112,000 -570,000 -1.7M -2.24M -3.64M
Share-based compensation (USD) 6.38M 6.62M 5.96M 9.81M 13M 22.5M 26.7M 33.1M 36.2M 43.6M
Operating cash flow before change in receivables (USD) -22.7M -20M -13.1M 2.93M -10.7M -23.1M 12M 40.3M 81.5M 137M
Free cash flow (OCF - PPE - intangibles) (USD) -32.2M -25.7M -15.4M -5.99M -12.5M -37M -1.01M 34.3M 63.8M 127M
Income detail
Research and development expense (USD) 15.3M 13.9M 14.8M 14.9M 17.2M 29.8M 40.6M 57.3M 69.3M 70.8M
↳ 5y CAGR +18.1% +16.0% +13.7% +8.7% +6.1% +14.3% +23.9% +31.1% +36.1% +32.7%
Total comprehensive income (USD) -31.4M -31M -23M -12.6M -34.9M -90.6M -52.8M -67.1M 12.1M 94.2M
Comprehensive income to owners (USD) -31.4M -31M -23M -12.6M -34.9M -90.6M -52.8M -67.1M 12.1M 94.2M
Provision for credit losses (USD) 68,000 0.00 0.00 — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 1.1% 0.0% 0.0% — — — — — — —
Reported Mar 1, 2017 Feb 25, 2019 Apr 30, 2019 Feb 25, 2020 Feb 28, 2022 Feb 28, 2022 Mar 1, 2023 Feb 29, 2024 Feb 28, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

PDF Version

Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share repurchase program

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.

“We delivered solid third quarter results supported by strong profitability and cash generation,” said Marc Stapley, chief executive officer of Veracyte. “Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”

Key Financial Highlights

For the three-month period ended September 30, 2026, as compared to the same period in 2025:

  • Increased total revenue by 15% to $151.8 million and testing revenue by 15% to $146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and Afirma growth of 19% to $51.5 million.

  • Increased total volume by 15% to 52,744 tests and testing volume by 13% to 49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.

  • Increased product revenue by 40% to $4.6 million, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO.

  • Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered adjusted EBITDA of $41.2 million, or 27.2% of revenue.

  • Generated $40.3 million of cash from operations to end the quarter with $370.5 million of cash, cash equivalents, and short-term investments as of September 30, 2026.

Key Business Highlights

  • Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.

  • Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer.

  • Further expanded the clinical evidence of the Decipher Prostate test, with new predictive evidence supporting its use with treatment intensification decisions across intermediate-risk and very high-risk prostate cancer.

  • Surpassed a key milestone, with more than 1 million patients served to date with Veracyte's tests.

  • Announced that the Board of Directors has authorized a share repurchase program for up to $100 million of common stock.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."

Third****Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $151.8 million, an increase of 15% compared to $131.9 million reported in the third quarter of 2025. Testing revenue was $146.4 million, an increase of 15% compared to $127.8 million in the third quarter of 2025, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared to $3.3 million in the third quarter of 2025, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8 million in the third quarter of 2025.

Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the third quarter of 2025.

Operating expenses were $90.5 million for the third quarter of 2026 compared to $68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24% to $72.9 million compared to $58.6 million in the third quarter of 2025.

GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of $12.4 million compared to the third quarter of 2025. Diluted net earnings per common share was $0.38, an improvement of $0.14 compared to the third quarter of 2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to the third quarter of 2025. Net cash provided by operating activities in the first nine months of 2026 was $121.3 million, an improvement of $37.6 million compared to the same period in 2025.

Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement of 4% compared to the third quarter of 2025, representing 27.2% of revenue.

2026 Financial Outlook Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million. This reflects testing revenue of $571 million to $573 million, representing 16% growth, compared to prior guidance of $576 million to $582 million, with minimal revenue contribution from recently launched tests. Further, the company continues to expect adjusted EBITDA margin of greater than 26% for 2026.

The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA margin to expected GAAP net income margin, the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.

Share Repurchase Program

Veracyte announced today that its Board of Directors has authorized a share repurchase program for up to $100 million of its common stock. Under the repurchase program, the company may repurchase shares through open market purchases, privately negotiated transactions or by other methods from time to time. Any open market repurchases will be structured to comply with applicable federal securities laws, including the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing, manner, price, and amount of any repurchases will be determined at the company's discretion based on a variety of factors, including market conditions, the trading price of the company's common stock, the company's financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors the company deems relevant. The repurchase program does not obligate the company to acquire any specific number of shares, may be modified, suspended, or discontinued at any time without prior notice at the discretion of the Board of Directors, and will expire after 12 months. The company currently expects to fund the repurchase program from available cash and cash equivalents.

Conference Call and Webcast Details Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; our share repurchase program, including the timing, amount and source of funds for any repurchases of shares; and our intentions with respect to the development, launch, commercialization, adoption, and reimbursement of our tests and products. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to our acquisitions, including C2i Genomics and Convergent Genomics, Inc., integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

Note Regarding Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.

We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

| VERACYTE, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |

| (Unaudited) |

| (In thousands, except share and per share amounts) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 |

| Revenue: | | | | | | | |

| Testing revenue | $ | 146,419 | | | $ | 127,756 | | | $ | 427,171 | | | $ | 357,328 |

| Product revenue | | 4,626 | | | | 3,301 | | | | 12,163 | | | | 10,479 |

| Biopharmaceutical and other revenue | | 709 | | | | 815 | | | | 1,812 | | | | 8,702 |

| Total revenue | | 151,754 | | | | 131,872 | | | | 441,146 | | | | 376,509 |

| | | | | | | | |

| Cost of revenue: (1) | | | | | | | |

| Cost of testing revenue | | 38,477 | | | | 33,777 | | | | 108,092 | | | | 94,444 |

| Cost of product revenue | | 2,766 | | | | 3,015 | | | | 7,172 | | | | 6,186 |

| Cost of biopharmaceutical and other revenue | | 142 | | | | 1,091 | | | | 357 | | | | 7,361 |

| Intangible asset amortization - cost of revenue | | 3,265 | | | | 2,707 | | | | 8,713 | | | | 7,959 |

| Total cost of revenue | | 44,650 | | | | 40,590 | | | | 124,334 | | | | 115,950 |

| Gross profit | | 107,104 | | | | 91,282 | | | | 316,812 | | | | 260,559 |

| Operating expenses: (1) | | | | | | | |

| Research and development | | 32,159 | | | | 15,981 | | | | 88,699 | | | | 49,965 |

| Selling and marketing | | 28,652 | | | | 24,455 | | | | 84,071 | | | | 74,225 |

| General and administrative | | 29,302 | | | | 27,278 | | | | 80,425 | | | | 93,417 |

| Impairment of assets | | — | | | | — | | | | — | | | | 20,505 |

| Intangible asset amortization - operating expenses | | 422 | | | | 622 | | | | 1,422 | | | | 1,865 |

| Total operating expenses | | 90,535 | | | | 68,336 | | | | 254,617 | | | | 239,977 |

| Income from operations | | 16,569 | | | | 22,946 | | | | 62,195 | | | | 20,582 |

| Other income (loss), net | | 4,553 | | | | (4,057 | ) | | | 15,424 | | | | 6,985 |

| Income before income taxes | | 21,122 | | | | 18,889 | | | | 77,619 | | | | 27,567 |

| Income tax provision (benefit) | | (10,381 | ) | | | (248 | ) | | | (8,081 | ) | | | 2,363 |

| Net income | $ | 31,503 | | | $ | 19,137 | | | $ | 85,700 | | | $ | 25,204 |

| Earnings per share: | | | | | | | |

| Basic | $ | 0.39 | | | $ | 0.24 | | | $ | 1.07 | | | $ | 0.32 |

| Diluted | $ | 0.38 | | | $ | 0.24 | | | $ | 1.04 | | | $ | 0.32 |

| Shares used to compute earnings per common share: | | | | | | | |

| Basic | | 80,500,406 | | | | 78,725,139 | | | | 80,006,663 | | | | 78,384,184 |

| Diluted | | 82,783,915 | | | | 79,691,703 | | | | 82,204,307 | | | | 79,946,386 |

  1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 |

| Cost of revenue | $ | 995 | | $ | 540 | | $ | 3,054 | | $ | 1,668 |

| Research and development | | 2,742 | | | 1,949 | | | 8,340 | | | 6,023 |

| Selling and marketing | | 2,734 | | | 2,102 | | | 7,839 | | | 6,258 |

| General and administrative | | 7,488 | | | 6,166 | | | 21,573 | | | 18,751 |

| Total stock-based compensation expense | $ | 13,959 | | $ | 10,757 | | $ | 40,806 | | $ | 32,700 |

| VERACYTE, INC. |

| CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME |

| (Unaudited) |

| (In thousands) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | 2025 |

| Net income | $ | 31,503 | | | $ | 19,137 | | | $ | 85,700 | | $ | 25,204 |

| Other comprehensive income (loss): | | | | | | | |

| Change in currency translation adjustments | | (122 | ) | | | (4,556 | ) | | | 151 | | | 19,575 |

| Release of accumulated translation adjustment | | — | | | | 8,295 | | | | — | | | 8,295 |

| Other comprehensive income (loss) | | (122 | ) | | | 3,739 | | | | 151 | | | 27,870 |

| Net comprehensive income | $ | 31,381 | | | $ | 22,876 | | | $ | 85,851 | | $ | 53,074 |

| VERACYTE, INC. |

| CONDENSED CONSOLIDATED BALANCE SHEETS |

| (In thousands) |

| | | | |

| | September 30, | | December 31, |

| | | 2026 | | | 2025 |

| | (Unaudited) | | (See Note 1) |

| Assets | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 199,828 | | $ | 362,578 |

| Short-term investments | | 170,704 | | | 50,311 |

| Accounts receivable | | 56,788 | | | 44,660 |

| Supplies | | 25,818 | | | 20,546 |

| Prepaid expenses and other current assets | | 14,740 | | | 10,281 |

| Total current assets | | 467,878 | | | 488,376 |

| Property, plant and equipment, net | | 24,870 | | | 22,192 |

| Right-of-use assets, operating leases | | 35,097 | | | 36,599 |

| Intangible assets, net | | 184,883 | | | 89,148 |

| Goodwill | | 855,575 | | | 767,154 |

| Restricted cash | | 1,646 | | | 1,648 |

| Other assets | | 3,307 | | | 902 |

| Total assets | $ | 1,573,256 | | $ | 1,406,019 |

| Liabilities and Stockholders’ Equity | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 9,710 | | $ | 4,593 |

| Accrued liabilities | | 60,087 | | | 48,801 |

| Current portion of deferred revenue | | 864 | | | 1,160 |

| Current portion of acquisition-related contingent consideration | | 6,734 | | | 1,332 |

| Current portion of operating lease liabilities | | 6,814 | | | 4,051 |

| Total current liabilities | | 84,209 | | | 59,937 |

| Deferred tax liabilities | | 1,616 | | | 646 |

| Acquisition-related contingent consideration, net of current portion | | 17,245 | | | 257 |

| Operating lease liabilities, net of current portion | | 33,922 | | | 35,603 |

| Other liabilities | | 3,000 | | | — |

| Total liabilities | | 139,992 | | | 96,443 |

| Total stockholders’ equity | | 1,433,264 | | | 1,309,576 |

| Total liabilities and stockholders’ equity | $ | 1,573,256 | | $ | 1,406,019 |

| | | | |

| 1. The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026. |

| VERACYTE, INC. |

| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |

| (Unaudited) |

| (In thousands) |

| | | | |

| | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | |

| Operating activities | | | |

| Net income | $ | 85,700 | | | $ | 25,204 | |

| Adjustments to reconcile net income to net cash provided by operating activities: | | | |

| Depreciation and amortization | | 16,247 | | | | 16,117 | |

| Loss on disposal of property, plant and equipment | | 367 | | | | 15 | |

| Stock-based compensation | | 40,806 | | | | 32,700 | |

| Deferred income taxes | | (11,599 | ) | | | (13 | ) |

| Noncash lease expense | | 2,088 | | | | 2,289 | |

| Revaluation of acquisition-related contingent consideration | | (1,110 | ) | | | (2,713 | ) |

| Effect of foreign currency on operations | | (23 | ) | | | (3,845 | ) |

| Amortization of discount on short-term investments | | (2,380 | ) | | | (2,619 | ) |

| Impairment loss | | — | | | | 20,505 | |

| Non-cash loss on deconsolidation of subsidiary | | — | | | | 3,863 | |

| Changes in operating assets and liabilities: | | | |

| Accounts receivable | | (11,963 | ) | | | (3,858 | ) |

| Supplies | | (3,435 | ) | | | (2,642 | ) |

| Prepaid expenses and other current assets | | (4,112 | ) | | | (6,416 | ) |

| Other assets | | (771 | ) | | | 331 | |

| Operating lease liabilities | | 496 | | | | (1,681 | ) |

| Accounts payable | | 5,522 | | | | (547 | ) |

| Accrued liabilities and deferred revenue | | 5,466 | | | | 7,034 | |

| Net cash provided by operating activities | | 121,299 | | | | 83,724 | |

| Investing activities | | | |

| Business acquisitions, net of cash acquired | | (153,190 | ) | | | — | |

| Purchase of short-term investments | | (234,997 | ) | | | (99,998 | ) |

| Proceeds from maturity of short-term investments | | 116,984 | | | | 102,116 | |

| Issuance of loan receivable | | (1,622 | ) | | | — | |

| Purchases of property, plant and equipment | | (8,155 | ) | | | (5,897 | ) |

| Net cash used in investing activities | | (280,980 | ) | | | (3,779 | ) |

| Financing activities | | | |

| Payment of taxes on vested restricted stock units | | (17,462 | ) | | | (14,645 | ) |

| Proceeds from the exercise of common stock options and employee stock purchases | | 14,493 | | | | 10,572 | |

| Net cash used in financing activities | | (2,969 | ) | | | (4,073 | ) |

| (Decrease) increase in cash, cash equivalents and restricted cash | | (162,650 | ) | | | 75,872 | |

| Effect of foreign currency on cash, cash equivalents and restricted cash | | (102 | ) | | | 707 | |

| Net (decrease) increase in cash, cash equivalents and restricted cash | | (162,752 | ) | | | 76,579 | |

| Cash, cash equivalents and restricted cash at beginning of period | | 364,226 | | | | 240,631 | |

| Cash, cash equivalents and restricted cash at end of period | $ | 201,474 | | | $ | 317,210 | |

| | | | |

| CASH, CASH EQUIVALENTS AND RESTRICTED CASH |

| (Unaudited) |

| (In thousands) |

| | | | |

| | September 30, | | December 31, |

| | | 2026 | | | 2025 |

| Cash and cash equivalents | $ | 199,828 | | $ | 362,578 |

| Restricted cash | | 1,646 | | | 1,648 |

| Total cash, cash equivalents and restricted cash | $ | 201,474 | | $ | 364,226 |

| VERACYTE, INC. |

| RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES |

| (Unaudited) |

| (In thousands) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Reconciliation of Non-GAAP Cost of Revenue: | | | | | | | |

| GAAP cost of testing revenue | $ | 38,477 | | | $ | 33,777 | | | $ | 108,092 | | | $ | 94,444 | |

| Stock-based compensation expense | | (994 | ) | | | (555 | ) | | | (3,052 | ) | | | (1,543 | ) |

| Acquisition related expenses (1) | | (131 | ) | | | — | | | | (131 | ) | | | — | |

| Other adjustments (2) | | (316 | ) | | | — | | | | (954 | ) | | | — | |

| Non-GAAP cost of testing revenue | $ | 37,036 | | | $ | 33,222 | | | $ | 103,955 | | | $ | 92,901 | |

| | | | | | | | |

| GAAP cost of product revenue | | 2,766 | | | | 3,015 | | | | 7,172 | | | | 6,186 | |

| Stock-based compensation expense | | (1 | ) | | | — | | | | (2 | ) | | | (2 | ) |

| Acquisition related expenses (1) | | — | | | | — | | | | — | | | | — | |

| Other adjustments (2) | | — | | | | (1,418 | ) | | | 11 | | | | (1,450 | ) |

| Non-GAAP cost of product revenue | $ | 2,765 | | | $ | 1,597 | | | $ | 7,181 | | | $ | 4,734 | |

| | | | | | | | |

| GAAP cost of biopharmaceutical and other revenue | | 142 | | | | 1,091 | | | | 357 | | | | 7,361 | |

| Stock-based compensation expense | | — | | | | 15 | | | | — | | | | (123 | ) |

| Acquisition related expenses (1) | | — | | | | — | | | | — | | | | — | |

| Other adjustments (2) | | — | | | | — | | | | — | | | | — | |

| Non-GAAP cost of biopharmaceutical and other revenue | $ | 142 | | | $ | 1,106 | | | $ | 357 | | | $ | 7,238 | |

| | | | | | | | |

| Reconciliation of Non-GAAP Gross Margin: | | | | | | | |

| GAAP Gross Profit | $ | 107,104 | | | $ | 91,282 | | | $ | 316,812 | | | $ | 260,559 | |

| GAAP Gross Margin | | 70.6 | % | | | 69.2 | % | | | 71.8 | % | | | 69.2 | % |

| Amortization of intangible assets | | 3,265 | | | | 2,707 | | | | 8,713 | | | | 7,959 | |

| Stock-based compensation expense | | 995 | | | | 540 | | | | 3,054 | | | | 1,668 | |

| Acquisition related expenses (1) | | 131 | | | | — | | | | 131 | | | | — | |

| Other adjustments (2) | | 316 | | | | 1,418 | | | | 943 | | | | 1,450 | |

| Non-GAAP Gross Profit | $ | 111,811 | | | $ | 95,947 | | | $ | 329,653 | | | $ | 271,636 | |

| Non-GAAP Gross Margin | | 73.7 | % | | | 72.8 | % | | | 74.7 | % | | | 72.1 | % |

| | | | | | | | |

| 1.Includes transaction-related expenses. For the three months and nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with acquisition activities ($0.1M). |

| 2.For the three months ended September 30, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3 million). For the three months ended September 30, 2025, adjustments include expenses related to Veracyte SAS investment review. For the nine months ended September 30, 2026, adjustments include the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.9 million), partially offset by expense related to the restructuring of Veracyte SAS. For the nine months ended September 30, 2025, adjustments include expenses related to Veracyte SAS investment review. |

| VERACYTE, INC. |

| RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES |

| (Unaudited) |

| (In thousands) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Reconciliation of Non-GAAP Operating Expenses: | | | | | | | |

| GAAP research and development | $ | 32,159 | | | $ | 15,981 | | | $ | 88,699 | | | $ | 49,965 | |

| Stock-based compensation expense | | (2,742 | ) | | | (1,949 | ) | | | (8,340 | ) | | | (6,023 | ) |

| Acquisition related expenses (1) | | (1 | ) | | | — | | | | (1 | ) | | | — | |

| Other adjustments (2) | | (176 | ) | | | — | | | | (652 | ) | | | — | |

| Non-GAAP research and development | $ | 29,240 | | | $ | 14,032 | | | $ | 79,706 | | | $ | 43,942 | |

| | | | | | | | |

| GAAP sales and marketing | $ | 28,652 | | | $ | 24,455 | | | $ | 84,071 | | | $ | 74,225 | |

| Stock-based compensation expense | | (2,734 | ) | | | (2,102 | ) | | | (7,839 | ) | | | (6,258 | ) |

| Acquisition related expenses (1) | | — | | | | — | | | | — | | | | — | |

| Other adjustments (2) | | (45 | ) | | | — | | | | (124 | ) | | | — | |

| Non-GAAP sales and marketing | $ | 25,873 | | | $ | 22,353 | | | $ | 76,108 | | | $ | 67,967 | |

| | | | | | | | |

| GAAP general and administrative | $ | 29,302 | | | $ | 27,278 | | | $ | 80,425 | | | $ | 93,417 | |

| Stock-based compensation expense | | (7,488 | ) | | | (6,166 | ) | | | (21,573 | ) | | | (18,751 | ) |

| Acquisition related expenses (1) | | (1,321 | ) | | | (166 | ) | | | (635 | ) | | | (593 | ) |

| Other adjustments (2) | | (2,694 | ) | | | 1,308 | | | | (6,516 | ) | | | (6,530 | ) |

| Non-GAAP general and administrative | $ | 17,799 | | | $ | 22,254 | | | $ | 51,701 | | | $ | 67,543 | |

| | | | | | | | |

| GAAP total operating expenses | $ | 90,535 | | | $ | 68,336 | | | $ | 254,617 | | | $ | 239,977 | |

| Amortization of intangible assets | | (422 | ) | | | (622 | ) | | | (1,422 | ) | | | (1,865 | ) |

| Stock-based compensation expense | | (12,964 | ) | | | (10,217 | ) | | | (37,752 | ) | | | (31,032 | ) |

| Acquisition related expenses (1) | | (1,322 | ) | | | (166 | ) | | | (636 | ) | | | (593 | ) |

| Other adjustments (2) | | (2,915 | ) | | | 1,308 | | | | (7,292 | ) | | | (27,035 | ) |

| Non-GAAP total operating expenses | $ | 72,912 | | | $ | 58,639 | | | $ | 207,515 | | | $ | 179,452 | |

| | | | | | | | |

| 1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent Genomics, Inc. (“Convergent”) ($1.7 million) partially offset with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent ($1.7 million) partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). |

| 2.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3 million). For the three months ended September 30, 2025, adjustments primarily include a vendor legal settlement ($2.8 million) partially offset by expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.0 million) and other legal proceedings ($0.5 million). For the nine months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.9 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and related to the restructuring and liquidation proceedings of Veracyte SAS ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million). |

| VERACYTE, INC. |

| RECONCILIATION OF U.S. GAAP to NON-GAAP FINANCIAL MEASURES |

| (Unaudited) |

| (In thousands) |

| | | | | | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Reconciliation of Adjusted EBITDA: | | | | | | | |

| GAAP Net Income (Loss) | $ | 31,503 | | | $ | 19,137 | | | $ | 85,700 | | | $ | 25,204 | |

| GAAP Net Income (Loss) as a % of Revenue | | 20.8 | % | | | 14.5 | % | | | 19.4 | % | | | 6.7 | % |

| Amortization of intangible assets | | 3,687 | | | | 3,329 | | | | 10,135 | | | | 9,824 | |

| Depreciation expense | | 2,293 | | | | 1,938 | | | | 6,112 | | | | 6,293 | |

| Stock-based compensation expense | | 13,959 | | | | 10,757 | | | | 40,806 | | | | 32,700 | |

| Acquisition related expenses (1) | | 1,453 | | | | 166 | | | | 767 | | | | 593 | |

| Other expense (income), net (2) | | (4,503 | ) | | | (3,484 | ) | | | (11,865 | ) | | | (9,630 | ) |

| Other adjustments (3) | | 3,231 | | | | 8,138 | | | | 4,423 | | | | 32,876 | |

| Income tax expense (benefit) | | (10,381 | ) | | | (248 | ) | | | (8,081 | ) | | | 2,363 | |

| Adjusted EBITDA | $ | 41,242 | | | $ | 39,733 | | | $ | 127,997 | | | $ | 100,223 | |

| Adjusted EBITDA as a % of Revenue | | 27.2 | % | | | 30.1 | % | | | 29.0 | % | | | 26.6 | % |

| | | | | | | | |

| Reconciliation of Non-GAAP Net Income (Loss) | | | | | | | |

| GAAP Net Income (Loss) | $ | 31,503 | | | $ | 19,137 | | | $ | 85,700 | | | $ | 25,204 | |

| Amortization of intangible assets | | 3,687 | | | | 3,329 | | | | 10,135 | | | | 9,824 | |

| Stock-based compensation expense | | 13,959 | | | | 10,757 | | | | 40,806 | | | | 32,700 | |

| Acquisition related expenses (1) | | 1,453 | | | | 166 | | | | 767 | | | | 593 | |

| Other adjustments (3) | | 3,231 | | | | 8,138 | | | | 4,423 | | | | 32,876 | |

| Tax adjustments (4) | | (11,971 | ) | | | (565 | ) | | | (13,526 | ) | | | (807 | ) |

| Non-GAAP Net Income | $ | 41,862 | | | $ | 40,962 | | | $ | 128,305 | | | $ | 100,390 | |

| | | | | | | | |

| Reconciliation of Non-GAAP Earnings per Share | | | | | | | |

| Diluted earnings per share, GAAP | $ | 0.38 | | | $ | 0.24 | | | $ | 1.04 | | | $ | 0.32 | |

| Amortization of intangible assets | | 0.04 | | | | 0.04 | | | | 0.12 | | | | 0.12 | |

| Stock-based compensation expense | | 0.17 | | | | 0.13 | | | | 0.50 | | | | 0.41 | |

| Acquisition related expenses (1) | | 0.02 | | | | — | | | | 0.01 | | | | 0.01 | |

| Other adjustments (3) | | 0.04 | | | | 0.10 | | | | 0.05 | | | | 0.41 | |

| Tax adjustments (4) | | (0.14 | ) | | | (0.01 | ) | | | (0.16 | ) | | | (0.01 | ) |

| Rounding and impact of dilutive shares | | — | | | | 0.01 | | | | — | | | | — | |

| Diluted earnings per share, non-GAAP | $ | 0.51 | | | $ | 0.51 | | | $ | 1.56 | | | $ | 1.26 | |

| | | | | | | | |

| Weighted average shares outstanding used in computing diluted earnings per share | | | | | | | |

| Diluted, GAAP | | 82,783,915 | | | | 79,691,703 | | | | 82,204,307 | | | | 79,946,386 | |

| Dilutive effect of equity awards (5) | | — | | | | — | | | | — | | | | — | |

| Diluted, non-GAAP | | 82,783,915 | | | | 79,691,703 | | | | 82,204,307 | | | | 79,946,386 | |

| | | | | | | | |

| 1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset by contingent consideration related to the NanoString transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). |

| 2.Includes interest income and income related to research tax credits. |

| 3.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million). For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7 million), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3 million), the restructuring and liquidation proceedings of Veracyte SAS ($2.4 million), and other legal proceedings ($0.5 million), partially offset by vendor legal settlement ($2.8 million). For the nine months ended September 30, 2026, adjustments primarily include expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), and losses related to asset disposition ($0.4 million), partially offset by adjustments related to the restructuring and liquidation proceedings of Veracyte SAS ($4.2 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and Veracyte SAS investment review ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million) and additional exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($3.6 million). |

| 4.Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. |

| 5.In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method. |

Investors: Kelly Gura [email protected]

Media: Molly Cornbleet [email protected] +1-650-351-8780

Contact Investor Relations

Please feel free to contact us if you have questions or would like additional investor relations information:

[email protected] +1 619.393.1545

Subscribe to Investor Alerts

Sign up

November 2, 2026

PDF Version

Two oral presentations mark Afirma’s strongest podium presence in recent years, alongside eight posters

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 10 abstracts involving its Afirma thyroid test will be presented at the 2026 Annual Meeting of the American Thyroid Association (ATA), November 4–7 in Philadelphia. The conference includes two oral presentations and eight posters, with five studies conducted independently of Veracyte.

The studies explore how gene expression can provide insights beyond individual genetic alterations to inform thyroid nodule diagnosis and assessment of cancer aggressiveness. Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets. Posters include studies using the Veracyte Genomic Resource for Intelligent Discovery (GRID) research database to investigate preoperative diagnosis and recurrence risk, as well as independent research on molecular testing and long-term outcomes.

“Patients facing a thyroid nodule diagnosis need to know whether they have cancer and, if they do, how that cancer might behave,” said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. “These studies build on Afirma’s long-established role in thyroid nodule diagnosis and explore how gene expression data can help researchers answer additional questions about cancer risk and biology.”

Afirma-related presentations at ATA 2026

Oral presentations

Title: Prostate-Specific Membrane Antigen (PSMA) mRNA Expression in Thyroid FNA Samples with Bethesda III-VI Cytology Predicts Lymphatic and Angioinvasion in Surgically Resected Tumors

  • Presenter: Wasim Najjar, MD, and Prasanna Santhanam, MD, Johns Hopkins University

  • Abstract #: O37

  • Date and time: Friday, November 6, 5:30-5:45 p.m. EST

  • Location: Salon H

Title: MRNA Analysis of Cell-Surface Protein Targets in Medullary Thyroid Cancer Fine Needle Aspiration Samples

  • Presenter: Sarah Hamidi, MD, MD Anderson Cancer Center

  • Abstract #: O27

  • Date and time: Thursday, November 5, 5:30-5:45 p.m. EST

  • Location: Salon H

Poster presentations

Title: Preoperative Transcriptomic Predictors of Benign or Malignant Thyroid Tumors without Expressed Variants and Fusions

  • Presenter: Eisha Gupta, MD and Arti Bhan, MD, Henry Ford Health

  • **Abstract #:**P311

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

Title: Preoperative Thyroid Nodule MRNA Expression Signatures to Predict 2025 Ata Risk of Recurrence for Differentiated Thyroid Cancer

  • Presenter: Eisha Gupta and Arti Bhan, Henry Ford

  • Abstract #: P310

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

Title: KEAP1 and NFE2L2 Mutations Drive NRF2 Pathway Activation in Indeterminate and Malignant Thyroid Nodules

  • Presenter: Taylor Cavazos, PhD, Veracyte, and Nicholas Bambach, MS, Children’s Hospital of Philadelphia

  • Abstract #: P229

  • Date and time: Thursday, November 5, 2:45-3:45 p.m. EST

  • Location: Franklin Hall

Independent poster presentations

Title: Invasion Signature Stratifies Malignancy and Invasive Pathology in Variant-Positive Indeterminate Thyroid Nodules

  • Presenter: David Allen, MD, New York Medical College

  • Abstract #: P145

  • Date and time: Thursday, November 5, 10:30-11:30 a.m. EST

  • Location: Franklin Hall

Title: Long-Term Follow-Up of Cytologically Indeterminate Afirma Gene Sequencing Classifier (GSC) Benign Nodules

  • Presenter: Janevi June Rebernigg, Sarasota Memorial Healthcare System

  • Abstract #: P326

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

Title: Long-Term Assessment of “Benign” Molecular Test Results in Indeterminate Thyroid Nodules: Should We Be Monitoring More Closely?

  • Presenter: Justin Bauzon, MD, Cleveland Clinic Foundation

  • Abstract #: P298

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

Title: Clinical Utility of Molecular Profiling in Nodules with Suspicious for Malignancy or Malignant Cytology

  • Presenter: Gilman Plitt, MD, PhD, Cleveland Clinic Foundation

  • **Abstract #:**P296

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

Title: Prevalence and Predictive Factors of Malignancy in Cytologically Indeterminate RAS-Mutant Thyroid Nodules

  • Presenter: Nathalie Silva De Morais, MD, PhD, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Mass General Brigham, Harvard Medical School

  • **Abstract #:**P615

  • Date and time: Friday, November 6, 2:15-3:15 p.m. EST

  • Location: Franklin Hall

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to the potential for gene expression analysis to inform thyroid nodule diagnosis and the assessment of cancer aggressiveness and recurrence risk and the potential for GRID to support research into thyroid cancer risk and biology. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at Veracyte Investor Relations. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Investors: Kelly Gura [email protected]

Media: Molly Cornbleet [email protected] +1 650-351-8780

Contact Investor Relations

Please feel free to contact us if you have questions or would like additional investor relations information:

[email protected] +1 619.393.1545

Subscribe to Investor Alerts

Sign up

October 29, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences:

  • UBS Global Healthcare Conference – Palm Beach Gardens, FL Fireside chat on Tuesday, November 10 at 4:15 p.m. Eastern Time

  • Jefferies Global Healthcare Conference – London, UK Fireside chat on Wednesday, November 18 at 2:30 p.m. Greenwich Mean Time

  • Stephens Annual Investment Conference – Nashville, TN Fireside chat on Thursday, November 19 at 9:30 a.m. Central Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).

Investors: Kelly Gura [email protected]

Media: Molly Cornbleet [email protected] +1-650-351-8780

Contact Investor Relations

Please feel free to contact us if you have questions or would like additional investor relations information:

[email protected] +1 619.393.1545

Subscribe to Investor Alerts

Sign up

Prompts

Veracyte, Inc. (ticker VCYT), listed in United States.

ETFs Holding Veracyte, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 2.47% 1,853,663 $ 44.914M Nov 18, 2026
HELX 1.64% 7,819 $ 459.21K Jun 30, 2026
TMAT 1.30% 66,839 $ 3.096M Jul 31, 2026
FMED 1.01% 12,021 $ 519.187K Aug 31, 2026
ARKK 0.85% 4,433,421 $ 107.422M Nov 18, 2026
JSML 0.84% 65,621 $ 3.04M Jul 31, 2026
GSC 0.76% 49,038 $ 2.118M Aug 31, 2026
JSMD 0.75% 170,470 $ 7.896M Jul 31, 2026
SQLV 0.44% 2,167 $ 127.268K Jun 30, 2026
ESSC 0.37% 2,856 $ 132.29K Jul 31, 2026
SEIS 0.33% 32,441 $ 1.905M Jun 30, 2026
FSEG 0.31% 304 $ 17.854K Jun 30, 2026
PSC 0.25% 101,008 $ 5.932M Jun 30, 2026
OASC 0.25% 5,452 $ 235.472K Aug 31, 2026
MMSC 0.22% 4,483 $ 107.637K Nov 16, 2026
RESM 0.15% 91 $ 5,344.43 Jun 30, 2026
FFSM 0.15% 47,077 $ 2.181M Jul 31, 2026
SMDX 0.14% 7,296 $ 175.177K Nov 17, 2026
AFSM 0.10% 5,842 $ 140.266K Nov 16, 2026
FESM 0.07% 70,160 $ 4.12M Jun 30, 2026
EBI 0.06% 9,152 $ 395.275K Aug 31, 2026
DFAT 0.05% 644,337 $ 15.87M Nov 12, 2026
DFAS 0.04% 608,236 $ 14.981M Nov 12, 2026
MSSM 0.02% 3,678 $ 158.853K Aug 31, 2026
VFMO 0.02% 8,800 $ 380.072K Aug 31, 2026
DXUV 0.02% 38,165 $ 940.004K Nov 12, 2026
DFSU 0.01% 11,109 $ 273.615K Nov 12, 2026
DFAC 0.01% 358,474 $ 8.829M Nov 12, 2026
DCOR 0.01% 135,730 $ 3.343M Nov 12, 2026
DFSV 0.00% 47,395 $ 1.167M Nov 12, 2026
DFAU 0.00% 20,947 $ 515.925K Nov 12, 2026
DFUS 0.00% 24,376 $ 600.381K Nov 12, 2026
AVUS 0.00% 5,495 $ 131.935K Nov 16, 2026
AVSU 0.00% 78 $ 1,872.78 Nov 16, 2026